Quet.Ns
Quetell operates in the pharmaceuticals industry, focusing on the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. Quetell operates in the pharmaceuticals industry, focusing on the development, manufacturing, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Quetell operates in the pharmaceuticals industry, focusing on the development, manufacturing, and sale of prescription drugs and related healthcare products.
Quetell's capital structure is characterized by a debt-to-equity ratio of 0.37, indicating a relatively conservative leverage position compared to the industry median of 0.52. The company's liquidity position is assessed as medium, with a current ratio of 2.88, which is above the industry median of 2.10. However, the company reported negative operating cash flow of INR 233.25 million, which contrasts with a positive free cash flow of INR 107.31 million, suggesting that capital expenditures are being funded internally.
In terms of profitability, Quetell's return on equity (ROE) of 16.58% is below the industry median of 21.40%, and its return on assets (ROA) of 11.15% is also below the median of 14.20%. The company's net income of INR 135.66 million represents a net margin of 13.04%, which is slightly above the industry median of 12.30%. These figures suggest that while Quetell is profitable, it is not outperforming its peers in terms of asset and equity utilization.
Quetell's revenue is concentrated in a single business segment, with no disclosed geographic breakdown. The company's revenue of INR 1,039.66 million is derived from its pharmaceutical products and services. There is no indication of significant geographic diversification, and the company's exposure to any single market is not specified in the available data.
The company's growth trajectory is modest, with no disclosed revenue growth rate for the current fiscal year. The outlook for the next fiscal year is not provided, but the company's capital expenditure of INR 34.71 million suggests a cautious approach to expansion. The company's free cash flow of INR 107.31 million indicates that it has the capacity to fund operations and potentially invest in growth opportunities.
Quetell's risk profile is marked by a medium liquidity risk and a low dilution risk. The company's shares outstanding are the same for both basic and diluted shares, indicating no imminent dilution pressure. The risk assessment also notes that the company has negative net cash after subtracting total debt, which could pose a liquidity challenge if not managed effectively.
Recent events related to Quetell include the latest financial filing, which provides the most recent financial data. There are no disclosed recent earnings calls or transcripts that provide additional insight into the company's strategic direction or operational performance.
- Quetell maintains a conservative debt-to-equity ratio of 0.37, which is below the industry median of 0.52.
- The company's ROE of 16.58% is below the industry median of 21.40%, indicating room for improvement in equity utilization.
- Quetell's free cash flow of INR 107.31 million suggests the company has the financial flexibility to fund operations and potential growth initiatives.
- The company's liquidity position is assessed as medium, with a current ratio of 2.88, which is above the industry median of 2.10.
- Quetell's risk profile is characterized by a low dilution risk and a medium liquidity risk, with no imminent dilution pressure.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- QUET.NS Market data — financials · 2026-05-29